Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Market Cap	64.08B
Revenue (ttm)	18.58B
Net Income (ttm)	5.07B
Shares Out	265.35M
EPS (ttm)	19.23
PE Ratio	12.56
Forward PE	11.80
Dividend	5.73 (2.28%)
Ex-Dividend Date	Aug 5, 2024

Volume	1,891,725
Average Volume	1,398,336
Open	250.50
Previous Close	251.00
Day's Range	240.50 - 250.50
52-Week Range	210.50 - 347.00
Beta	0.44
RSI	27.89
Earnings Date	Mar 14, 2025

About Lotus Pharmaceutical

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products. In addition, it engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemica...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1966
• Employees: 1,099
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1795

Financial Performance

In 2024, Lotus Pharmaceutical's revenue was 18.58 billion, an increase of 9.59% compared to the previous year's 16.96 billion. Earnings were 5.07 billion, an increase of 23.38%.